Jubilant Pharmova Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,370 Cr +20.5% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
JP

Jubilant Pharmova Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Jubilant Pharmova Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹1,966Cr
+12.2% YoY
+3.4% QoQ
Net profit
₹120Cr
+17.6% YoY
+17.6% QoQ
Margin
17%
0 pp YoY
+2 pp QoQ

Based on Jubilant Pharmova Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,064
Market cap₹17.0K Cr
P/E43.7

The short version

Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables. Q2’FY26 Financials:.

From Jubilant Pharmova Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables.
  • H1’FY26 revenue grew by 11% YoY to Rs. 3,867 Cr. across all business units.
  • Radiopharmaceuticals Q2’FY26 revenue rose 16% YoY to Rs. 291 Cr.
  • Radiopharmacy Q2’FY26 revenue increased 7% YoY to Rs. 607 Cr.
  • Allergy Immunotherapy Q2’FY26 revenue increased 14% YoY to Rs. 194 Cr.
  • CDMO Sterile Injectables Q2’FY26 revenue rose 30% YoY to Rs. 393 Cr.
  • Generics Q2’FY26 revenue fell 3% YoY to Rs. 167 Cr.
  • API Q2’FY26 revenue up 8% YoY to Rs. 137 Cr.

2 more points from Jubilant Pharmova Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Spokane, USA:
  • Line 3 Sterile Fill & Finish line launched with a total investment of USD 132 million.
  • Technology transfer programs ongoing; commercial production expected FY27.
  • Line 4 expansion on track; commercial production expected FY28.
  • Combined revenue potential for Lines 3 & 4: USD 160-180 million.
  • Montreal Facility, Canada:
  • Shutdown in Q2’FY26 for quality improvements; restart expected Q3’FY26.
  • USD 114 million investment for expansion of sterile fill & lyophilization operations.
  • USD 40 million concessional loans from Canadian Government; rest from internal accruals.
  • New sterile ophthalmic plant (200-bottle/min) undergoing validation; commercial qualification expected by end FY26.
  • Drug Discovery Services:
  • Capacity expansion from 1,000 FTEs in FY25 to 4,000 FTEs by FY30.

2 more points from Jubilant Pharmova Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Jubilant Pharmova Ltd Q2 FY26 results — key figures

Jubilant Pharmova Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue1,9661,752+12.2%1,901+3.4%
Operating profit (EBITDA)341289+18%290+17.6%
Operating margin17%17%0 pp15%+2 pp
Profit before tax190144+31.9%154+23.4%
Net profit (PAT)120102+17.6%102+17.6%
EPS (₹)7.556.45+17.1%6.46+16.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.4K Cr, net profit ₹31 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jubilant Pharmova Ltd Q2 FY26 results?

Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables. Q2’FY26 Financials:.

What is Jubilant Pharmova Ltd share price analysis?

Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Pharmova Ltd planning capital expenditure?

Spokane, USA: - Line 3 Sterile Fill & Finish line launched with a total investment of USD 132 million.

Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.